Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia

Blood

Volumn 95, Issue 4, 2000, Pages 1229-1236

  Davis, Bernard A ^a   Porter, John B ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CATHETER INFECTION; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS CATHETER; LONG TERM CARE; MALE; PRIORITY JOURNAL; RETINOPATHY; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0034651775     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1229.004k32_1229_1236     Document Type: Article

References (41)

1. Zurlo MF, De Stefano P, Borgna-Pignatti C. et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27.
2. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331:574.
3. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Eng J Med. 1994;331:567.
4. Gabutti V, Piga A. Results of long term iron chelating therapy. Acta Haematol. 1996;95:26.
5. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JWP. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73: 403.
6. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739.
7. Porter JB. A risk-benefit assessment of iron chelation therapy. Drug Saf. 1997;17:407.
8. Cohen AR, Martin M, Schwartz E. Current treatment of Cooley's anemia. Ann N Y Acad Sci. 1990;612:286.
9. Tamary H, Goshen J, Carmi D, et al. Long-term intravenous deferoxamine treatment for non-compliant transfusion dependent beta-thalassemia patients. Isr J Med Sci. 1994;30:658.
10. Marcus RE, Davies SC, Bantock HM. Underwood SR, Wallon S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet. 1984;1: 392.
11. Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation Acta Haematol. 1990;84:113.
12. Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. Am J Hematol. 1992;41:61.
13. Walton S. Radionuclide ventriculography. In: Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Vol 1. London, England: Churchill Livingstone; 1994:1069.
14. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 1984;68:873.
15. Araujo A, Kosaryan M, MacDowell A, et al. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br J Haematol. 1996;93:835.
16. Russell SJ, Giles FJ, Edwards D, Porter JB, Hardmann S, Harrison R. Perforation of superior vena cava by indwelling central venous catheters. Lancet. 1987;1:568.
17. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30: 698.
18. Olivieri NF, Snider MA, Nathan DG, et al. Survival following the onset of iron-induced cardiac disease in thalassemia major. Blood. 1995;86(abstr 985, suppl 1):250a.
19. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med. 1985;106:147.
20. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci (Colch). 1985;68:463.
21. Link G, Athias P, Grynberg A, Pinson A, Hershko C. Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. J Lab Clin Med. 1989;113: 103.
22. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88:705.
23. Crichton RR, Roman F, Roland F. Iron mobilisation from ferritin by chelating agents. J Inorg Biochem. 1980;13:305.
24. Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin A: patients with homozygous β thalassaemia and transfusional iron overload. Br J Haematol. 1980;46:409.
25. Decker MD, Edwards KM. Central venous catheter infections. Pediatr Clin North Am. 1988;35: 579.
26. Elliot TSJ, Faroqui MH. Infections and intravascular devices. Br J Hosp Med. 1992;48:498.
27. Gaziev D, Baronciani D, Galimberti M, et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant. 1996;17: 409.
28. Sands JM, Macher AM, Ley TJ, Nienhuis AW. Disseminated infection caused by Cunninghamella bertholletiae in a patient with beta-thalassemia. Ann Intern Med. 1985;102:59.
29. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18:660.
30. Tebbs SE, Elliott TSJ. Modification of central venous catheter polymers to prevent in vitro microbial colonisation. Eur J Clin Microbiol Infect Dis. 1994;13:111.
31. Tebbs SE, Elliott TSJ. A novel antimicrobial central venous catheter impregnated with benzalkonium chloride. J Antimicrob Chemother. 1993;31: 261.
32. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med. 1997;127:257.
33. Raad I, Darouiche R, Dupuis J, et al, and the Texas Medical Center Catheter Study Group. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. Ann Intern Med. 1997;127:267.
34. Lokich JJ, Bothe A, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol. 1985;3:710.
35. Strum S, McDermed J, Korn A, Joseph C. Improved methods for venous access: the Port-A-Cath, a totally implanted catheter system. J Clin Oncol. 1986;4:596.
36. Shulman RJ, Rahman S, Mahoney D, Pokorny WJ, Bloss R. A totally implanted venous access system used in pediatric patients with cancer. J Clin Oncol. 1987;5:137.
37. Stillman RM, Soliman F, Garcia L, Sawyer PN. Etiology of catheter-associated sepsis: correlation with thrombogenicity. Arch Surg. 1977;112: 1497.
38. Pruitt BA, McManus WF, Kim SH, Treat RC. Diagnosis and treatment of cannula-related intravenous sepsis in burn patients. Ann Surg. 1980;191:546.
39. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine. 1984;63:189.
40. Topiel MS, Bryan RT, Kessler CM, Simon GL. Case report: treatment of silastic catheter-induced central vein septic thrombophlebitis. Am J Med Sci. 1986;291:425.
41. BCSH guidelines on oral anticoagulation: third edition. Br J Haematol. 1998;101:374.